재생의료 시장 : 시장 분석 및 예측 - 유형별, 제품별, 서비스별, 기술별, 용도별, 재료 유형별, 디바이스별, 프로세스별, 최종 사용자별(-2035년)

The global regenerative medicine market is projected to grow from $41.3 billion in 2025 to $194.6 billion by 2035, at a compound annual growth rate (CAGR) of 16.8%. The Regenerative Medicine Market is characterized by a moderately consolidated structure, with cell therapy representing the leading segment due to its expanding applications in oncology, musculoskeletal disorders, and genetic diseases, followed by gene therapy and tissue engineering. The market is driven by advancements in stem cell technologies, CRISPR-based gene editing, increasing clinical trials, and rising regulatory approvals for regenerative therapies. The competitive landscape includes major biotechnology and pharmaceutical companies focusing on innovation, partnerships, and manufacturing expansion. For instance, in January 2025, Genenta Science strengthened its agreement with AGC Biologics to establish a dedicated GMP manufacturing suite for its cell therapy product, enhancing production capabilities for advanced cell-based therapies.

Based on Type, the Cell Therapy segment dominated the Regenerative Medicine Market in 2025 due to its extensive clinical applications, increasing adoption in advanced therapeutic development, and strong presence across multiple disease areas. Cell therapy involves the use of living cells to repair damaged tissues, replace dysfunctional cells, and restore biological functions, making it highly valuable in oncology, orthopedic disorders, cardiovascular diseases, and neurological conditions. Growing advancements in stem cell technologies, immune cell therapies, and cell manufacturing processes are accelerating its adoption. Increasing investments from biotechnology and pharmaceutical companies, expanding clinical pipelines, and rising regulatory approvals continue to strengthen the leadership position of cell therapy in the global regenerative medicine market.

Based on Technology, the 3D Bioprinting segment is projected to register the fastest growth during the forecast period, driven by its ability to develop complex biological structures, customized tissues, and advanced scaffolds with high precision. The technology enables researchers to replicate natural tissue architectures, supporting innovations in tissue engineering, organ regeneration, and personalized medicine. Increasing investments in regenerative research, advancements in biomaterials, and growing collaborations between biotechnology companies, academic institutions, and healthcare organizations are accelerating the adoption of 3D bioprinting solutions. Rising demand for innovative approaches to address organ shortages, improve transplantation outcomes, and develop patient-specific therapies is expected to further drive the rapid expansion of this segment.

Geographical Overview

North America dominated the Regenerative Medicine Market in 2025, supported by advanced healthcare infrastructure, strong biotechnology ecosystems, extensive research activities, and significant investments in cell and gene therapy development. The United States represents the largest contributor due to the presence of leading biotechnology and pharmaceutical companies, a high number of clinical trials, and a favorable regulatory environment supporting regenerative therapy approvals. Canada also contributes to regional growth through government-backed research initiatives and increasing investments in advanced medical technologies. Strong collaborations between academic institutions, research organizations, and industry players continue to strengthen North America's leadership position in the global regenerative medicine market.

Asia-Pacific region is projected to register the fastest growth in the Regenerative Medicine Market during the forecast period, driven by increasing healthcare investments, expanding biotechnology capabilities, rising research activities, and a large patient population with unmet medical needs. Countries such as China, Japan, South Korea, and India are witnessing rapid advancements in stem cell research, gene therapy, and tissue engineering applications. Government initiatives supporting biotechnology innovation, growing clinical trial activities, and increasing collaborations between regional and global healthcare companies are accelerating market expansion. Additionally, improving healthcare infrastructure and rising adoption of advanced therapeutic solutions are expected to further support the rapid growth of regenerative medicine across the region.

Key Trends and Drivers

Advances in Stem Cell Technologies:

The regenerative medicine market is witnessing significant growth due to continuous advancements in stem cell technologies. Innovations in stem cell isolation, expansion, and differentiation are enabling the development of advanced therapies for conditions such as neurological disorders, cardiovascular diseases, and musculoskeletal injuries. These technologies are supporting the development of personalized regenerative treatments by allowing patient-specific cell-based approaches. Increasing investments from biotechnology companies, pharmaceutical firms, and research institutions are accelerating innovation in stem cell applications. Additionally, improvements in cell manufacturing processes and quality control are enhancing the scalability and commercialization potential of stem cell-based regenerative therapies.

Increasing Adoption of Cell and Gene Therapies:

The regenerative medicine market is being driven by the growing adoption of cell and gene therapies for treating complex and previously difficult-to-treat medical conditions. Advances in gene editing technologies, including CRISPR-based approaches, and the development of engineered cell therapies are expanding treatment possibilities across oncology, genetic disorders, and rare diseases. Increasing clinical trial activities, regulatory approvals, and investments from pharmaceutical and biotechnology companies are accelerating the commercialization of these therapies. The ability of regenerative approaches to address underlying disease mechanisms rather than only managing symptoms is further increasing demand for innovative therapeutic solutions globally.

Research Scope

• Estimates and forecasts the overall market size across type, application, and region.
• Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
• Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
• Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
• Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
• Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
• Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

• 1.1 Market Size and Forecast
• 1.2 Market Overview
• 1.3 Market Snapshot
• 1.4 Regional Snapshot
• 1.5 Strategic Recommendations
• 1.6 Analyst Notes

2 Market Highlights

• 2.1 Key Market Highlights by Type
• 2.2 Key Market Highlights by Product
• 2.3 Key Market Highlights by Technology
• 2.4 Key Market Highlights by Application
• 2.5 Key Market Highlights by End User
• 2.6 Key Market Highlights by Process
• 2.7 Key Market Highlights by Services
• 2.8 Key Market Highlights by Device
• 2.9 Key Market Highlights by Material Type

3 Market Dynamics

• 3.1 Macroeconomic Analysis
• 3.2 Market Trends
• 3.3 Market Drivers
• 3.4 Market Opportunities
• 3.5 Market Restraints
• 3.6 CAGR Growth Analysis
• 3.7 Impact Analysis
• 3.8 Emerging Markets
• 3.9 Technology Roadmap
• 3.10 Strategic Frameworks
  • 3.10.1 PORTER's 5 Forces Model
  • 3.10.2 ANSOFF Matrix
  • 3.10.3 4P's Model
  • 3.10.4 PESTEL Analysis

4 Segment Analysis

• 4.1 Market Size & Forecast by Type (2020-2035)
  • 4.1.1 Cell Therapy
  • 4.1.2 Gene Therapy
  • 4.1.3 Tissue Engineering
  • 4.1.4 Stem Cell Therapy
  • 4.1.5 Immunotherapy
  • 4.1.6 Others
• 4.2 Market Size & Forecast by Product (2020-2035)
  • 4.2.1 Scaffolds
  • 4.2.2 Biomaterials
  • 4.2.3 Stem Cell Products
  • 4.2.4 Gene Editing Tools
  • 4.2.5 Cell Culture Products
  • 4.2.6 Others
• 4.3 Market Size & Forecast by Technology (2020-2035)
  • 4.3.1 CRISPR
  • 4.3.2 TALEN
  • 4.3.3 Zinc Finger Nucleases
  • 4.3.4 Cell Culture Technology
  • 4.3.5 Bioreactor Technology
  • 4.3.6 3D Bioprinting
  • 4.3.7 Others
• 4.4 Market Size & Forecast by Application (2020-2035)
  • 4.4.1 Orthopedic & Musculoskeletal Disorders
  • 4.4.2 Dermatology
  • 4.4.3 Cardiovascular
  • 4.4.4 Neurology
  • 4.4.5 Oncology
  • 4.4.6 Diabetes
  • 4.4.7 Ophthalmology
  • 4.4.8 Wound Care
  • 4.4.9 Others
• 4.5 Market Size & Forecast by End User (2020-2035)
  • 4.5.1 Hospitals
  • 4.5.2 Clinics
  • 4.5.3 Research Institutes
  • 4.5.4 Biotechnology Companies
  • 4.5.5 Pharmaceutical Companies
  • 4.5.6 Academic Institutes
  • 4.5.7 Others
• 4.6 Market Size & Forecast by Process (2020-2035)
  • 4.6.1 In Vivo
  • 4.6.2 Ex Vivo
  • 4.6.3 Others
• 4.7 Market Size & Forecast by Services (2020-2035)
  • 4.7.1 Regenerative Medicine Consulting
  • 4.7.2 Regenerative Medicine Manufacturing
  • 4.7.3 Regenerative Medicine R&D
  • 4.7.4 Others
• 4.8 Market Size & Forecast by Device (2020-2035)
  • 4.8.1 Bioreactors
  • 4.8.2 Cell Expansion Systems
  • 4.8.3 Cell Sorting Systems
  • 4.8.4 Others
• 4.9 Market Size & Forecast by Material Type (2020-2035)
  • 4.9.1 Natural Biomaterials
  • 4.9.2 Synthetic Biomaterials
  • 4.9.3 Hydrogels
  • 4.9.4 Nanomaterials
  • 4.9.5 Others

5 Regional Analysis

• 5.1 Global Market Overview
• 5.2 North America Market Size (2020-2035)
  • 5.2.1 United States
    • 5.2.1.1 Type
    • 5.2.1.2 Product
    • 5.2.1.3 Technology
    • 5.2.1.4 Application
    • 5.2.1.5 End User
    • 5.2.1.6 Process
    • 5.2.1.7 Services
    • 5.2.1.8 Device
    • 5.2.1.9 Material Type
  • 5.2.2 Canada
    • 5.2.2.1 Type
    • 5.2.2.2 Product
    • 5.2.2.3 Technology
    • 5.2.2.4 Application
    • 5.2.2.5 End User
    • 5.2.2.6 Process
    • 5.2.2.7 Services
    • 5.2.2.8 Device
    • 5.2.2.9 Material Type
  • 5.2.3 Mexico
    • 5.2.3.1 Type
    • 5.2.3.2 Product
    • 5.2.3.3 Technology
    • 5.2.3.4 Application
    • 5.2.3.5 End User
    • 5.2.3.6 Process
    • 5.2.3.7 Services
    • 5.2.3.8 Device
    • 5.2.3.9 Material Type
• 5.3 Latin America Market Size (2020-2035)
  • 5.3.1 Brazil
    • 5.3.1.1 Type
    • 5.3.1.2 Product
    • 5.3.1.3 Technology
    • 5.3.1.4 Application
    • 5.3.1.5 End User
    • 5.3.1.6 Process
    • 5.3.1.7 Services
    • 5.3.1.8 Device
    • 5.3.1.9 Material Type
  • 5.3.2 Argentina
    • 5.3.2.1 Type
    • 5.3.2.2 Product
    • 5.3.2.3 Technology
    • 5.3.2.4 Application
    • 5.3.2.5 End User
    • 5.3.2.6 Process
    • 5.3.2.7 Services
    • 5.3.2.8 Device
    • 5.3.2.9 Material Type
  • 5.3.3 Rest of Latin America
    • 5.3.3.1 Type
    • 5.3.3.2 Product
    • 5.3.3.3 Technology
    • 5.3.3.4 Application
    • 5.3.3.5 End User
    • 5.3.3.6 Process
    • 5.3.3.7 Services
    • 5.3.3.8 Device
    • 5.3.3.9 Material Type
• 5.4 Asia-Pacific Market Size (2020-2035)
  • 5.4.1 China
    • 5.4.1.1 Type
    • 5.4.1.2 Product
    • 5.4.1.3 Technology
    • 5.4.1.4 Application
    • 5.4.1.5 End User
    • 5.4.1.6 Process
    • 5.4.1.7 Services
    • 5.4.1.8 Device
    • 5.4.1.9 Material Type
  • 5.4.2 India
    • 5.4.2.1 Type
    • 5.4.2.2 Product
    • 5.4.2.3 Technology
    • 5.4.2.4 Application
    • 5.4.2.5 End User
    • 5.4.2.6 Process
    • 5.4.2.7 Services
    • 5.4.2.8 Device
    • 5.4.2.9 Material Type
  • 5.4.3 South Korea
    • 5.4.3.1 Type
    • 5.4.3.2 Product
    • 5.4.3.3 Technology
    • 5.4.3.4 Application
    • 5.4.3.5 End User
    • 5.4.3.6 Process
    • 5.4.3.7 Services
    • 5.4.3.8 Device
    • 5.4.3.9 Material Type
  • 5.4.4 Japan
    • 5.4.4.1 Type
    • 5.4.4.2 Product
    • 5.4.4.3 Technology
    • 5.4.4.4 Application
    • 5.4.4.5 End User
    • 5.4.4.6 Process
    • 5.4.4.7 Services
    • 5.4.4.8 Device
    • 5.4.4.9 Material Type
  • 5.4.5 Australia
    • 5.4.5.1 Type
    • 5.4.5.2 Product
    • 5.4.5.3 Technology
    • 5.4.5.4 Application
    • 5.4.5.5 End User
    • 5.4.5.6 Process
    • 5.4.5.7 Services
    • 5.4.5.8 Device
    • 5.4.5.9 Material Type
  • 5.4.6 Taiwan
    • 5.4.6.1 Type
    • 5.4.6.2 Product
    • 5.4.6.3 Technology
    • 5.4.6.4 Application
    • 5.4.6.5 End User
    • 5.4.6.6 Process
    • 5.4.6.7 Services
    • 5.4.6.8 Device
    • 5.4.6.9 Material Type
  • 5.4.7 Rest of APAC
    • 5.4.7.1 Type
    • 5.4.7.2 Product
    • 5.4.7.3 Technology
    • 5.4.7.4 Application
    • 5.4.7.5 End User
    • 5.4.7.6 Process
    • 5.4.7.7 Services
    • 5.4.7.8 Device
    • 5.4.7.9 Material Type
• 5.5 Europe Market Size (2020-2035)
  • 5.5.1 Germany
    • 5.5.1.1 Type
    • 5.5.1.2 Product
    • 5.5.1.3 Technology
    • 5.5.1.4 Application
    • 5.5.1.5 End User
    • 5.5.1.6 Process
    • 5.5.1.7 Services
    • 5.5.1.8 Device
    • 5.5.1.9 Material Type
  • 5.5.2 France
    • 5.5.2.1 Type
    • 5.5.2.2 Product
    • 5.5.2.3 Technology
    • 5.5.2.4 Application
    • 5.5.2.5 End User
    • 5.5.2.6 Process
    • 5.5.2.7 Services
    • 5.5.2.8 Device
    • 5.5.2.9 Material Type
  • 5.5.3 United Kingdom
    • 5.5.3.1 Type
    • 5.5.3.2 Product
    • 5.5.3.3 Technology
    • 5.5.3.4 Application
    • 5.5.3.5 End User
    • 5.5.3.6 Process
    • 5.5.3.7 Services
    • 5.5.3.8 Device
    • 5.5.3.9 Material Type
  • 5.5.4 Spain
    • 5.5.4.1 Type
    • 5.5.4.2 Product
    • 5.5.4.3 Technology
    • 5.5.4.4 Application
    • 5.5.4.5 End User
    • 5.5.4.6 Process
    • 5.5.4.7 Services
    • 5.5.4.8 Device
    • 5.5.4.9 Material Type
  • 5.5.5 Italy
    • 5.5.5.1 Type
    • 5.5.5.2 Product
    • 5.5.5.3 Technology
    • 5.5.5.4 Application
    • 5.5.5.5 End User
    • 5.5.5.6 Process
    • 5.5.5.7 Services
    • 5.5.5.8 Device
    • 5.5.5.9 Material Type
  • 5.5.6 Rest of Europe
    • 5.5.6.1 Type
    • 5.5.6.2 Product
    • 5.5.6.3 Technology
    • 5.5.6.4 Application
    • 5.5.6.5 End User
    • 5.5.6.6 Process
    • 5.5.6.7 Services
    • 5.5.6.8 Device
    • 5.5.6.9 Material Type
• 5.6 Middle East & Africa Market Size (2020-2035)
  • 5.6.1 Saudi Arabia
    • 5.6.1.1 Type
    • 5.6.1.2 Product
    • 5.6.1.3 Technology
    • 5.6.1.4 Application
    • 5.6.1.5 End User
    • 5.6.1.6 Process
    • 5.6.1.7 Services
    • 5.6.1.8 Device
    • 5.6.1.9 Material Type
  • 5.6.2 United Arab Emirates
    • 5.6.2.1 Type
    • 5.6.2.2 Product
    • 5.6.2.3 Technology
    • 5.6.2.4 Application
    • 5.6.2.5 End User
    • 5.6.2.6 Process
    • 5.6.2.7 Services
    • 5.6.2.8 Device
    • 5.6.2.9 Material Type
  • 5.6.3 South Africa
    • 5.6.3.1 Type
    • 5.6.3.2 Product
    • 5.6.3.3 Technology
    • 5.6.3.4 Application
    • 5.6.3.5 End User
    • 5.6.3.6 Process
    • 5.6.3.7 Services
    • 5.6.3.8 Device
    • 5.6.3.9 Material Type
  • 5.6.4 Sub-Saharan Africa
    • 5.6.4.1 Type
    • 5.6.4.2 Product
    • 5.6.4.3 Technology
    • 5.6.4.4 Application
    • 5.6.4.5 End User
    • 5.6.4.6 Process
    • 5.6.4.7 Services
    • 5.6.4.8 Device
    • 5.6.4.9 Material Type
  • 5.6.5 Rest of MEA
    • 5.6.5.1 Type
    • 5.6.5.2 Product
    • 5.6.5.3 Technology
    • 5.6.5.4 Application
    • 5.6.5.5 End User
    • 5.6.5.6 Process
    • 5.6.5.7 Services
    • 5.6.5.8 Device
    • 5.6.5.9 Material Type

6 Market Strategy

• 6.1 Demand-Supply Gap Analysis
• 6.2 Trade & Logistics Constraints
• 6.3 Price-Cost-Margin Trends
• 6.4 Market Penetration
• 6.5 Consumer Analysis
• 6.6 Regulatory Snapshot

7 Competitive Intelligence

• 7.1 Market Positioning
• 7.2 Market Share
• 7.3 Competition Benchmarking
• 7.4 Top Company Strategies

8 Company Profiles

• 8.1 Novartis
  • 8.1.1 Overview
  • 8.1.2 Product Summary
  • 8.1.3 Financial Performance
  • 8.1.4 SWOT Analysis
• 8.2 Medtronic
  • 8.2.1 Overview
  • 8.2.2 Product Summary
  • 8.2.3 Financial Performance
  • 8.2.4 SWOT Analysis
• 8.3 Stryker
  • 8.3.1 Overview
  • 8.3.2 Product Summary
  • 8.3.3 Financial Performance
  • 8.3.4 SWOT Analysis
• 8.4 Amgen
  • 8.4.1 Overview
  • 8.4.2 Product Summary
  • 8.4.3 Financial Performance
  • 8.4.4 SWOT Analysis
• 8.5 Gilead Sciences
  • 8.5.1 Overview
  • 8.5.2 Product Summary
  • 8.5.3 Financial Performance
  • 8.5.4 SWOT Analysis
• 8.6 Baxter International
  • 8.6.1 Overview
  • 8.6.2 Product Summary
  • 8.6.3 Financial Performance
  • 8.6.4 SWOT Analysis
• 8.7 Vertex Pharmaceuticals
  • 8.7.1 Overview
  • 8.7.2 Product Summary
  • 8.7.3 Financial Performance
  • 8.7.4 SWOT Analysis
• 8.8 Biogen
  • 8.8.1 Overview
  • 8.8.2 Product Summary
  • 8.8.3 Financial Performance
  • 8.8.4 SWOT Analysis
• 8.9 Regeneron Pharmaceuticals
  • 8.9.1 Overview
  • 8.9.2 Product Summary
  • 8.9.3 Financial Performance
  • 8.9.4 SWOT Analysis
• 8.10 Astellas Pharma
  • 8.10.1 Overview
  • 8.10.2 Product Summary
  • 8.10.3 Financial Performance
  • 8.10.4 SWOT Analysis
• 8.11 Organogenesis
  • 8.11.1 Overview
  • 8.11.2 Product Summary
  • 8.11.3 Financial Performance
  • 8.11.4 SWOT Analysis
• 8.12 Vericel Corporation
  • 8.12.1 Overview
  • 8.12.2 Product Summary
  • 8.12.3 Financial Performance
  • 8.12.4 SWOT Analysis
• 8.13 Osiris Therapeutics
  • 8.13.1 Overview
  • 8.13.2 Product Summary
  • 8.13.3 Financial Performance
  • 8.13.4 SWOT Analysis
• 8.14 Mesoblast
  • 8.14.1 Overview
  • 8.14.2 Product Summary
  • 8.14.3 Financial Performance
  • 8.14.4 SWOT Analysis
• 8.15 Fate Therapeutics
  • 8.15.1 Overview
  • 8.15.2 Product Summary
  • 8.15.3 Financial Performance
  • 8.15.4 SWOT Analysis
• 8.16 Bluebird Bio
  • 8.16.1 Overview
  • 8.16.2 Product Summary
  • 8.16.3 Financial Performance
  • 8.16.4 SWOT Analysis
• 8.17 Sangamo Therapeutics
  • 8.17.1 Overview
  • 8.17.2 Product Summary
  • 8.17.3 Financial Performance
  • 8.17.4 SWOT Analysis
• 8.18 Athersys
  • 8.18.1 Overview
  • 8.18.2 Product Summary
  • 8.18.3 Financial Performance
  • 8.18.4 SWOT Analysis
• 8.19 Pluristem Therapeutics
  • 8.19.1 Overview
  • 8.19.2 Product Summary
  • 8.19.3 Financial Performance
  • 8.19.4 SWOT Analysis
• 8.20 Cytori Therapeutics
  • 8.20.1 Overview
  • 8.20.2 Product Summary
  • 8.20.3 Financial Performance
  • 8.20.4 SWOT Analysis

9 About Us

• 9.1 About Us
• 9.2 Research Methodology
• 9.3 Research Workflow
• 9.4 Consulting Services
• 9.5 Our Clients
• 9.6 Client Testimonials
• 9.7 Contact Us